Advicenne S.A. (EPA:ALDVI)

Market Cap	26.64M +22.0%
Revenue (ttm)	5.90M -5.4%
Net Income	-6.21M
EPS	-0.50
Shares Out	14.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,603
Average Volume	34,096
Open	1.912
Previous Close	1.910
Day's Range	1.850 - 1.912
52-Week Range	1.104 - 2.350
Beta	0.85
RSI	42.04
Earnings Date	Mar 26, 2026

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. wa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALDVI

Financial Performance

In 2024, Advicenne's revenue was 5.27 million, a decrease of -0.51% compared to the previous year's 5.30 million. Losses were -6.46 million, -14.13% less than in 2023.